Argon Plasma Coagulation vs Hemoclipping for Bleeding Peptic Ulcers
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Rebleeding |
3; 4 | — |
| SECONDARY Mortality |
0; 1 | — |
| SECONDARY Surgery or Arterial Embolization |
0; 1 | — |
Eligibility Criteria
Inclusion Criteria
． high-risk peptic ulcer bleeding. High-risk bleeding ulcers were defined as participants with stigmata of a bleeding visible vessels (eg, spurting, oozing), a non-bleeding visible vessels (NBVV) or adherent clot.4 A NBVV at endoscopy was defined as a raised red, red-blue or pale hemispheric vessel protruding from the ulcer bed, without active bleeding. An adherent clot was defined as an overlying blood clot that was resistant to vigorous irrigation.
Exclusion Criteria
- the presence of another possible bleeding site (eg, gastroesophageal varix, gastric cancer, reflux esophagitis)
- coexistence of actively severe ill diseases (eg, septic shock, stroke, myocardial infarction, surgical abdomen)
- treatment with an anticoagulant (eg, warfarin)
- pregnancy
- the presence of operated stomach
- refusal to participate in the study
Data sourced from ClinicalTrials.gov (NCT04366583). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.